Q BioMed Inc. engages in the acquisition, development, and financing of biomedical assets. The company offers Strontium Chloride Sr-89/Metastron, a radiopharmaceutical for the treatment of metastatic cancer bone pain. It also develops various preclinical candidates comprising QBM-001 for rare pediatric non-verbal autism spectrum disorder; UTTROSIDE-B, a chemotherapeutic for liver cancer; and MAN-01, a topical eyedrops for glaucoma. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.